ArticleJournal of inflammation research2026
Eleutheroside E Attenuates Hypobaric Hypoxia-Induced High Altitude Pulmonary Edema by Regulating Ferritinophagy-Mediated Ferroptosis via Keap1-Nrf2 Regulatory Axis.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eleutheroside E is a natural lignan and high-altitude pulmonary edema (HAPE) is a noncardiogenic pulmonary edema induced by exposure to a high-altitude environment. The present study is designed to investigate the therapeutic effects of eleutheroside E against HAPE in rats. Methods: In this study, Sprague-Dawley rats were placed in a hypobaric hypoxia chamber (simulated altitude of 6,000 m; partial pressure of oxygen: 9.6 kPa) for 48 h of continuous exposure and treated with varying doses of eleutheroside E to evaluate its therapeutic effects against HAPE. To investigate the mechanism by which eleutheroside E regulates ferritinophagy and ferroptosis via the Keap1-Nrf2 axis, rescue experiments were performed using the autophagy inhibitor 3-MA, the ferroptosis agonist RSL3, and the Nrf2 inhibitor ML385. The therapeutic effects were validated by utilizing hematoxylin and eosin (H&E) staining, arterial blood gas analysis, lung wet/dry weight ratio, and inflammation cytokines. Furthermore, ferritinophagy-mediated ferroptosis was detected by transmission electron microscope, immunofluorescence staining, and Western blotting. Oxidative stress was detected by associated kits and reactive oxygen species levels. Results: The administration of eleutheroside E alleviated HAPE in rats, and it could correct hypoxia and suppress lipid oxidation induced by hypobaric hypoxia. Moreover, it decreased the levels of inflammation cytokines, VEGF, and total proteins in the bronchoalveolar lavage fluid of rats. Autophagy was found to be involved in the pathological process of HAPE, specifically in the form of ferritinophagy, which represents a novel type of autophagy. The anti-ferritinophagy-mediated ferroptosis effects of eleutheroside E were confirmed by using transmission electron microscopy and Western blotting. The involvement of the Keap1-Nrf2 axis in eleutheroside E-mediated inhibition of ferritinophagy-driven ferroptosis was confirmed by rescue experiments. Conclusion: In summary, eleutheroside E exhibits therapeutic effects against HAPE in rats by suppressing ferritinophagy-mediated ferroptosis via the Keap1-Nrf2 axis. This study indicated a prospective role of eleutheroside E as a functional component in preventing HAPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.